These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 1827721

  • 1. Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial.
    Aulitzky WE, Tilg H, Gastl G, Mull R, Flener R, Vogel W, Herold M, Berger M, Judmaier G, Huber C.
    Eur J Cancer; 1991; 27(4):462-7. PubMed ID: 1827721
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy.
    Zamkoff KW, Newman NB, Rudolph AR, Young J, Poiesz BJ.
    J Biol Response Mod; 1989 Oct; 8(5):539-52. PubMed ID: 2795095
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.
    Jakubowski AA, Casper ES, Gabrilove JL, Templeton MA, Sherwin SA, Oettgen HF.
    J Clin Oncol; 1989 Mar; 7(3):298-303. PubMed ID: 2918329
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.
    Kurzrock R, Feinberg B, Talpaz M, Saks S, Gutterman JU.
    J Interferon Res; 1989 Aug; 9(4):435-44. PubMed ID: 2502584
    [Abstract] [Full Text] [Related]

  • 5. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
    Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF.
    J Clin Oncol; 1987 Dec; 5(12):1942-51. PubMed ID: 3681377
    [Abstract] [Full Text] [Related]

  • 6. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
    Aulitzky WE, Tilg H, Herold M, Berger M, Vogel W, Judmaier G, Gastl G, Mull B, Flener R, Wiegele J.
    J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer.
    Negrier MS, Pourreau CN, Palmer PA, Ranchere JY, Mercatello A, Viens P, Blaise D, Jasmin C, Misset JL, Franks CR.
    J Immunother (1991); 1992 Feb; 11(2):93-102. PubMed ID: 1571336
    [Abstract] [Full Text] [Related]

  • 8. Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): a phase one study.
    IJzermans JN, van der Schelling GP, Scheringa M, Splinter TA, Marquet RL, Jeekel J.
    Neth J Surg; 1991 Aug; 43(4):121-5. PubMed ID: 1944989
    [Abstract] [Full Text] [Related]

  • 9. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.
    Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU.
    J Clin Oncol; 1988 Aug; 6(8):1328-34. PubMed ID: 3411344
    [Abstract] [Full Text] [Related]

  • 10. [Systemic versus local therapy with recombinant tumor necrosis factor-alpha (r-TNF-alpha) in patients with advanced tumors].
    Bartsch HH, Pfizenmaier K, Schröder M, Nagel GA.
    Onkologie; 1989 Jun; 12(3):136-41. PubMed ID: 2668836
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ.
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.
    Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD.
    Cancer Res; 1991 Mar 15; 51(6):1651-8. PubMed ID: 1998956
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor.
    van der Schelling GP, IJzermans JN, Kok TC, Scheringa M, Marquet RL, Splinter TA, Jeekel J.
    Eur J Cancer; 1992 Mar 15; 28A(6-7):1073-8. PubMed ID: 1627378
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.
    Gamm H, Lindemann A, Mertelsmann R, Herrmann F.
    Eur J Cancer; 1991 Mar 15; 27(7):856-63. PubMed ID: 1834117
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group).
    Agosti JM, Coombs RW, Collier AC, Paradise MA, Benedetti JK, Jaffe HS, Corey L.
    AIDS Res Hum Retroviruses; 1992 May 15; 8(5):581-7. PubMed ID: 1515211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.